807 results about "Acid derivative" patented technology

Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivativesThe invention relates to 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives of the general formula (I) and their agrochemically acceptable saltsand to their use in the crop protection sector.

Disclosed herein are antimicrobial compounds, polymorphic forms, compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

A method for improving health conditions of mammals or livestock by feeding, to the mammals or livestock, a licorice extract including: (A) glycyrrhizic acid, a glycyrrhizic acid derivative, glycyrrhetinic acid, and / or a glycyrrhetinic acid derivative; (B) licorice saponins other than (A); and (C) licorice flavonoids; (B) including at least a licorice saponin H2, a licorice saponin G2, and macedonoside A, (C) including at least liquiritin apioside, isoliquiritin apioside, and isoliquiritin, where feeding is of 0.017 g / day / head or more of the licorice saponin H2, 0.002 g / day / head or more of the licorice saponin G2, and 0.002 g / day / head or more of the macedonoside A, 0.001 g / day / head or more of the liquiritin apioside, 0.001 g / day / head or more of the isoliquiritin apioside, and 0.001 g / day / head or more of the isoliquiritin.

The invention discloses a synthetic method of 2 '-fluoro-2'-deoxynucleosid-5 '-triphosphoric acid and application of the 2'-fluoro-2 '-deoxynucleosid-5'-triphosphoric acid. The synthesis method comprises the following steps: reacting in a system containing adenosine triphosphate, 2 '-fluoro-2'-deoxynucleoside, metal ions and deoxynucleoside kinase to obtain 2 '-fluoro-2'-deoxynucleoside-5 '-phosphoric acid; and reacting in a system containing polyphosphoric acid, 2 '-fluoro-2'-deoxynucleoside-5 '-phosphoric acid, metal ions and polyphosphate kinase to obtain 2'-fluoro-2 '-deoxynucleoside-5'-triphosphoric acid. The obtained 2 '-fluoro-2'-deoxynucleoside-5 '-triphosphoric acid can be used for preparing heterologous nucleic acid. The invention provides an economic and green new way for synthesis of 2 '-fluoro-2'-deoxynucleoside-5 '-triphosphate, solves the problems of complex steps, non-environment-friendly reagents and high cost in the existing chemical synthesis method, and provides a thought for preparation of nucleotide derivatives.

The present invention discloses a preparation method and application of 2-phenylindole derivatives. Palladium acetate and copper acetate are added into a glacial acetic acid solution of an indole derivative (formula I) and an arylphenylboronic acid derivative (formula II), stirred at room temperature, and purified to obtain a 2-phenylindole derivative (formula III). The present invention provides a method for direct one-step synthesis of 2-arylindole compounds from indole derivatives and arylphenylboronic acid derivatives as raw materials. The present invention replaces oxygen with air to participate in an oxidation system, expands substituents of indole ring R1, adds substitution of 5-bit, 6-bit and 7-bit electron withdrawing groups and electron donating groups, further expands the range of substrates, and increases the yield of substitution on indole ring R1 by about 13%, wherein 2-methyl and 3-methoxy substituted by R2 and 6-chlorine substituted by R1 have good antifungal activity.

To provide a method for producing 4-ketobenzamide derivatives and 4-ketobenzoic acid derivatives.SOLUTION: The present invention provides a method for producing a 4-ketobenzamide compound represented by formula (2), by amidating a compound represented by formula (1), which is obtained through cyanation of a compound represented by formula (3), as well as a method for producing a 4-ketobenzoic acid derivative represented by formula (6), by hydrolyzing the compound represented by formula (1) or the compound represented by formula (2), and a method for producing a 4-ketobenzoic acid ester derivative represented by formula (5), by esterifying the compound represented by formula (2), wherein R1 represents a C1-C6 alkyl group or the like, R2 represents a C1-C6 alkyl group or the like, R3 represents a C1-C6 alkyl group or the like, X represents a halogen atom or the like, Y represents a C1-C6 alkyl group or the like, and n represents an integer of 0-3.SELECTED DRAWING: None

The disclosure relates to the field of specialty chemicals and methods for their synthesis. In embodiments, the disclosure provides viable bacterial cells which comprise heterologous dual 3-hydroxy-acyl-ACP dehydratase / isomerases, etc. The disclosure further provides monounsaturated fatty acid derivative molecules produced by the viable bacterial cells which are non-native to the bacterial cells. The disclosure further provides methods for the preparation and production of non-native monounsaturated fatty acid derivative molecules such as e.g., an ω3-monounsaturated fatty acid derivative, an ω5-monounsaturated fatty acid derivative, an ω9-monounsaturated fatty acid derivative, an ω11-monounsaturated fatty acid fatty acid derivative, etc.

Provided is a combination therapy for an antitumor agent that exhibits a high antitumor effect using a pyridone carboxylic acid derivative.　An antitumor agent characterized by being administered in combination with other antitumor agents, and comprising, as an active ingredient, a compound represented by the formula (1) (in the formula, the wavy line represents the steric configuration being the R configuration or the S configuration) or a salt thereof, wherein the other antitumor agents are one or more types selected from cytarabine, venetoclax, azacitidine, gilteritinib, birabresib, vorinostat, GSK126, MK-8776, AZD7762, rabusertib, dabrafenib, vemurafenib, olaparib, adavosertib, alisertib, decitabine, midostaurin, and AZD5991.

The disclosure provides a substituted phenylpropionic acid derivative and a use thereof. Specifically, the disclosure provides a compound as shown in formula II or a medicinal salt thereof, which can be used in the preparation of a drug for preventing and / or treating cardiovascular diseases.

The invention belongs to the technical field of polymer synthetic materials, and particularly relates to bio-based MS resin and a preparation method thereof. The bio-based MS resin is a free radical copolymer of a methyl methacrylate monomer and a styrene monomer; the methyl methacrylate monomers comprise bio-based methyl methacrylate, isobornyl methacrylate and 3-pinane methacrylate, and the methyl methacrylate monomers comprise methyl methacrylate, isobornyl methacrylate and 3-pinane methacrylate; the styrene monomers comprise styrene and caffeic acid derivatives; based on 100% of the mass of the bio-based MS resin, the methacrylate monomer accounts for 30%; the molar ratio of caffeic acid derivatives to styrene in the styrene monomers is 1: (1-9). The synthesized bio-based MS resin has the characteristics of greenness and reproducibility, compared with petroleum-based MS resin, the performance of the MS resin can be regulated and controlled by designing a protecting group of a bio-based caffeic acid derivative so as to expand the application range of the MS resin, a specific functional group can be introduced to prepare a functional, advanced and high-performance polymer material, and the MS resin has a good market prospect.

The invention discloses an oil-controlling and acne-removing synergistic composition which comprises the following components in percentage by weight: 0.8 to 2.0 percent of succinic acid, 0.3 to 1.0 percent of salicylic acid derivative and 0.5 to 1.5 percent of PCA (Principal Component Analysis) zinc. The invention also provides a sustained-release body. The sustained-release body is prepared from the following components in percentage by weight: 0.8 to 2.0 percent of succinic acid, 0.3 to 1.0 percent of salicylic acid derivative, 0.5 to 1.5 percent of PCA zinc, 1.0 to 2.5 percent of lactobionic acid, 1.0 to 3.0 percent of lactobacillus fermentation product, 2.0 to 4.0 percent of aminated modified diatomite and 0.1 to 0.3 percent of citric acid. The invention also provides a preparation method and application of the sustained release body. The acne-removing shampoo has low irritation, and can be used for controlling oil and removing acnes for a long time and efficiently dredging hair follicles.

Provided are: a liquid crystal aligning agent which contains two or more polyamic acids and in which deterioration in liquid crystal aligning properties when stored at room temperature is suppressed; a liquid crystal alignment film obtained from the liquid crystal aligning agent; and a liquid crystal display element. The liquid crystal aligning agent is characterized by containing the following polymer (A) and polymer (B). Polymer (A): a polyamic acid (A) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (a-1Ta) represented by formula (1Ta), and containing, as the structural unit derived from the diamine, a structural unit (a-1Da) represented by formula (1Da), at least a part of the terminal of the polyamic acid (A) contains a non-amino group, the non-amino group is a functional group represented by structural formula (E), and the presence rate of the terminal amino group in the polyamic acid (A) is 60% or less based on the total terminal of the polyamic acid (A). Polymer (B): a polyamic acid (B) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid including a structural unit (b-1Tb) represented by formula (1Tb) as the structural unit derived from the tetracarboxylic acid derivative, and including a structural unit (b-1Db) represented by formula (1Db) as the structural unit derived from the diamine. (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification)

A hyaluronic acid derivative pharmaceutical composition comprising (A) a hyaluronic acid derivative into which a hydrophobic group is introduced, (B) an association promoter, and (C) an active ingredient. Preferably, the association accelerator (B) contains at least four ether structures (R-O-R), and satisfies the condition that the number of carbon atoms is 4 or more.

The invention discloses a compound mosquito larvae killing composition and application thereof. The compound mosquito larvae killing composition comprises 1% to 5% of active ingredients, 0% to 5% of liquid original drug adsorbent, and 2% to 8% of slow-release coating agent (including 1% to 4% of active ingredients A and active ingredients B, wherein the active ingredient A is a piperic acid derivative compound, and the active ingredient B is selected from any one of pyriproxyfen, fenthion, dimethoate, fenoxycarb, S-methoprene, dinotefuran, thiamethoxam, acetamiprid, imidacloprid, nitenpyram, cyantraniliprole, and chlorantraniliprole. The active ingredients A and B are compounded and processed into granules for mosquito larvae control, and the granules have good lethal effect, long lasting effect, slow-release effect, and reduced labor cost; the compound mosquito larvae killing composition can be widely used in sewage ditches, sewers, and other places, and has special effects on mosquito larvae control.

The invention relates to a degradable high-strength medical adhesive and a preparation method and application thereof.The medical adhesive is prepared from raw materials through reaction, the raw materials comprise a component A, a component B and a component C. The component A is trihydric alcohol and derivatives thereof and / or trihydric alcohol modified by polyethylene glycol carboxylic acid derivatives and derivatives thereof, and the component C is trihydric alcohol modified by polyethylene glycol carboxylic acid derivatives and derivatives thereof. The component B is isocyanate, amino acid or an amino acid derivative, and the component C is N-methyldiethanolamine and / or bis (2-ethoxyl)-N-methyl-N-trifluoromethyl ammonium iodide and a derivative of the bis (2-ethoxyl)-N-methyl-N-trifluoromethyl ammonium iodide; the molar ratio of-NCO groups in the component B to total-OH groups in the component A and the component C is 2: 1, and the molar ratio of the component A to the component C is (1-9): 2. The component A and the component C are mixed, heated and dissolved, then a catalyst and the component B are added, and a mixed reaction system is obtained; and cooling after the reaction is completed, adding a rheology modifier, a foaming catalyst and a stabilizer, and uniformly mixing to obtain the degradable high-strength medical adhesive which can be applied to a functional composite material.

The invention discloses a preserving fluid for stably preserving sample DNA at normal temperature and a preparation method thereof, and belongs to the technical field of biological sample preservation. The preserving fluid comprises a lysis system, a nucleic acid protection system and a buffering and stabilizing system, the cracking system comprises a composite surfactant and an enzymolysis auxiliary agent; the composite surface active agent is prepared from polyether polyol fatty acid ester and cocamidopropyl hydroxy sulfobetaine; the enzymolysis auxiliary agent comprises lysozyme Lyso-V and protease K; the nucleic acid protection system comprises a nitrogen heterocyclic polyamine-carboxylic acid derivative and dextran sulfate; the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N' ', N ''tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N''-triacetic acid, disodium ethylene diamine tetraacetate-nitrogen heterocyclic derivative, and diethylenetriamine pentaacetic acid-piperazine derivative, and the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N '', N'' tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N ''-triacetic acid. The buffering and stabilizing system comprises an amphoteric buffering agent and a polymer stabilizer; the amphoteric buffering agent comprises 2-(N-morpholino) ethanesulfonic acid and N-tri (hydroxymethyl) methylglycine.

The invention relates to the field of membrane material preparation, in particular to an amino acid derivative polymer membrane material and a preparation method thereof. The preparation method provided by the invention comprises the following steps: S1, preparing a polymer solution; S2, forming and depositing a membrane; S3, carrying out surface modification on the membrane; and S4, carrying out crosslinking treatment. The functional polymer membrane material is synthesized through the amino acid derivative, selective separation of specific ions or molecules can be achieved, and good biocompatibility, stability and application prospects are achieved. The technology can be widely applied to multiple fields of biological separation, environment purification, drug delivery and the like, and has remarkable innovativeness and practical value.

According to the method for synthesizing the 2-amino-3-hydroxy-4-oxobutyric acid derivative through enzyme catalysis, threonine aldolase LTA and / or threonine transaldolase LTTA are / is adopted for catalysis, and the 2-amino-3-hydroxy-4-oxobutyric acid derivative with double chiral centers can be efficiently and selectively synthesized.

Provided is a beverage that enables improvement of an unpleasant sensation of sweetness that remains on the tongue and / or a reduction in the sensation of freshness. According to one embodiment of the present invention, provided is a beverage that contains: cinnamic acid, a cinnamic acid derivative, or a combination thereof; an acidifier; and a sweetener; wherein the content of at least one of the cinnamic acid, the cinnamic acid derivative, or a combination thereof is 0.01-4 mg / 100 g, and the acidity in terms of citric acid is 0.65-2.5 g / 100 g.

The invention provides a phenylpropionic acid derivative, a preparation method thereof, an antioxidant and application, and belongs to the field of medicine and health and food industry. The phenylpropionic acid derivative is ethane-1, 2-diyl bis (3-(3, 5-di-tert-butyl-4-hydroxyphenyl)-propanoate, and the structural formula of the phenylpropionic acid derivative is shown in the specification, and the structural formula of the phenylpropionic acid derivative is shown in the specification, namely ethane-1, 2-diyl bis (3-(3, 5-di-tert-butyl-4-hydroxyphenyl)-propanoate. The invention provides a new application of the phenylpropionic acid derivative, and in-vitro tests prove that the phenylpropionic acid derivative provided by the invention has better in-vitro antioxidant activity, can be used as an active component of an antioxidant, and has wide application.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention relates to an acridine sulfonamide carboxylic acid derivative as well as a preparation method and application thereof, and the preparation method comprises the following steps: in an alkaline environment, acridine sulfonamide and amino acid or an amino acid derivative are subjected to amidation reaction in an organic solvent, and the acridine sulfonamide carboxylic acid derivative is obtained after purification; wherein the acridine sulfonamide carboxylic acid derivative has two acridine sulfonamide-like groups, and the two acridine sulfonamide-like groups are connected through the amino acid or the amino acid derivative. The yield of the preparation method exceeds 70%, and the luminous efficiency of the prepared acridine sulfonamide carboxylic acid derivative is higher and is about two times that of acridine sulfonamide NSP-SA-NHS.

The invention belongs to the technical field of biological medicines, and particularly relates to a royal jelly acid derivative and a synthesis method, a pharmaceutical composition and application thereof. The royal jelly acid derivative is a compound shown as a formula (I), or an enantiomer, a diastereoisomer and a tautomer thereof, or a solvate or a pharmaceutically acceptable salt thereof. A series of royal jelly acid derivatives with novel structures are constructed by using a natural component royal jelly acid derived from royal jelly as an initial raw material, the royal jelly acid derivatives can play a role in resisting pulmonary fibrosis by inhibiting the activity of fibroblasts, the effect of the royal jelly acid derivatives is equivalent to that of pirfenidone, and the royal jelly acid derivatives are expected to be developed into candidate drugs for resisting pulmonary fibrosis. The ceramide NP has excellent effects in anti-inflammatory, anti-allergic and itching-relieving aspects, has a better effect than known ceramide NP, and can be used for preparing health care products, cosmetics and medicines. And # imgabs0 #.

The invention belongs to the technical field of catalytic methods and catalysts, and particularly relates to a method for preparing a polysubstituted allene carboxylic acid methyl ester compound based on CO2 and photocatalysis, which is based on a photocatalytic reaction system, takes CO2 as a carboxyl source, and is prepared through a 1, 3-enyne 1, 3-polysubstituted allene carboxylic acid methyl ester compound under the mild conditions of no photocatalyst and metal, so that the polysubstituted allene carboxylic acid methyl ester compound is obtained. According to the present invention, the efficient synthesis of the polysubstituted allene carboxylic acid derivative is achieved through the 1, 4-alkane carboxylation reaction, the method has advantages of good yield, wide substrate universality, suitableness for the reaction of a variety of functional groups, non-toxicity of the used reagent, and wide application prospect.

The invention relates to a whitening composition and a preparation method and application thereof, and belongs to the technical field of whitening products.The whitening composition contains a tea extract, raspberry ketone glucoside, an ascorbic acid derivative, nicotinamide, tranexamic acid, hydroxyethyl piperazine ethanesulfonic acid, an opuntia streptacantha stem extract and a saxifraga stolonifera extract. The tea leaf extract, the opuntia streptacantha stem extract and the saxifraga stolonifera extract are products which are obtained through step-by-step enzymolysis of specific enzymes and are less than 2kDa. On the basis that an existing whitening product generally only has a single path and is poor in whitening effect, multiple whitening active raw materials are matched, multiple whitening paths with different action mechanisms are combined, the synergistic effect is achieved, the skin pigment problem caused by multiple factors is better solved, and safety and high efficiency are achieved.

The present invention relates to a 5-aminolevulinic acid derivative having improved storage stability and bioavailability, and a pharmaceutical composition comprising same, the present invention exhibiting pharmacokinetic characteristics in which 5-aminolevulinic acid is more effectively exposed to blood in the body, and alleviating side effects such as pain, erythema, swelling, edema, burning, itching, exfoliation, hyperpigmentation, and long-term irritation and hypersensitivity following treatment. In addition, the present invention relates to a 5-aminolevulinic acid derivative and a composition comprising same in which 5-aminolevulinic acid is highly effective while reducing the severity of side effects, and which can be used for photodynamic diagnosis and treatment.

The invention relates to a novel spirocyclopropane tetronic acid derivative with insecticidal and acaricidal activity as well as preparation and application of the novel spirocyclopropane tetronic acid derivative. Specifically, the invention provides a compound as shown in a formula (I), and an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has obvious insecticidal and acaricidal activity, and can be used for developing novel crop insecticidal and acaricidal agents which are low in toxicity, efficient and environment-friendly. # imgabs0 #

The invention relates to preparation and application of a desoxyribonucleic acid and desoxyribonucleic acid derivative transdermal delivery system, and belongs to the technical field of biological medicine and skin care products. Desoxyribonucleic acid and derivatives thereof have the effects of resisting aging, repairing and the like, but are difficult to penetrate through a skin barrier due to large molecular weight and strong polarity. According to the invention, hydroxyethyl chitosan, desoxyribonucleic acid and derivatives thereof are combined through electrostatic interaction to form the nano-composite. The compound is small in particle size and can promote transdermal absorption through hair follicle or cuticle gaps. The preparation method is simple, does not need an auxiliary reagent, and comprises the step of mixing a hydroxyethyl chitosan solution and a deoxyribonucleic acid derivative solution. Experiments show that the compound significantly enhances the transdermal efficiency, and has the effects of promoting cell repair and proliferation and resisting inflammation. The composition can be used for skin care products, and is high in safety and wide in application prospect.